RE:Stock Options Granted just before Critical UpdateRoseHeaven ... It indeeds all points to growth.
You don't grant stock options if you're in a dead end and if you don't have potential.
This morning's stock options news is another sign that growth in valuation is logically coming up as, so far, TLT has done everything it needed to do with TLD1433 for the NMIBC indication (all we're left to do is recruit additional patients (55) so they can close this Ph. 2 trial), and they brought Rutherrin to enough advancement so far (more to come for sure but at least, they know Rutherrin is mature enough to be brought into clinical trial against GBM and NSCLC). Not to mention the COVID-19 opportunity.
Of course, the granting of Breakthrough designation and Accelerated Approval is out of TLT's decision but TLT has done all it needed to do to get them.
It's fair though to be confident we will obtain one of them, if not both, given the definitions, the quality of our clinical data (efficacy), the unique characteristics of our treatment (low number of doses, low side effect, no BCG dependance, couple of cancer-free patients with a single dose, no patient discrimination (unlike imunitherapies), etc ...), the BCG shortage, the role of the FDA to spur innovation and offer aditional alternatives to patients away from BCG.